Lexicon Pharmaceuticals (LXRX) Total Liabilities (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Total Liabilities data on file, last reported at $66.0 million in Q1 2026.

• Total Liabilities for Q1 2026 came in at $66.0 million, down 62.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $66.0 million (down 62.23% YoY), and the FY2025 annual result was $77.4 million, down 49.2% from the prior year.
• Total Liabilities fell to $66.0 million in Q1 2026 per LXRX's latest filing, from $77.4 million in the prior quarter.
• Over five years, Total Liabilities peaked at $174.6 million in Q1 2025 and troughed at $41.5 million in Q2 2022.
• A 5-year average of $102.6 million and a median of $96.1 million in 2025 frame the typical range for Total Liabilities.
• The sharpest annual moves came in 2022 and 2026: Total Liabilities jumped 231.02% in 2022, then sank 62.23% in 2026.
• A 5-year view of Total Liabilities shows it stood at $77.2 million in 2022, then surged by 76.64% to $136.3 million in 2023, then increased by 11.85% to $152.5 million in 2024, then tumbled by 49.2% to $77.4 million in 2025, then slipped by 14.83% to $66.0 million in 2026.
• Business Quant data shows LXRX's Total Liabilities at $66.0 million in Q1 2026, $77.4 million in Q4 2025, and $85.8 million in Q3 2025.